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I~  Pulmonary deposition of inhaled tobramycin (TOBI), before and 
after physiotherapy and inhaled salbutamol and correlation with 
CF genotype 
M.13. Grotta 1, J. Romanato 2, E.C.S.C. Etchebehere 2, A.F. Ribeiro 1 , G. Hessel 1, 
C.S. 13ertuzzo 4, R13.M. Conti 3, E.E. Camargo 2, J.D. Ribeiro 1 . 1Department of 
Pediatrics, 2Nuclear Medicine, 3physiotherapy, 4Genetics, State University of 
Campinas Medical School, Unicamp, Brazil 
Patients with CF are often treated with inhaled antibiotics and physiotherapy. No 
study evaluating the pulmonary deposition of inhaled antibiotics before and after 
physiotherapy and bronchodilators has been found in literature. 
Aim: To evaluate TO13I pulmonary deposition before and after physiotherapy and 
inhaled salbutamol and to correlate with genotype. 
Methods: A clinical controlled, prospective study including CF patients colonized 
by P aeruginosa was done from July/November 2005. Exclusions criteria: pul- 
monary exacerbation at the scintigraphy moment, changes in medication between 
phase I and II, FEV1 < 25% predicted. Pulmonary scintigraphy was performed in 
a equipped camera with a LEAP collimator that showed the lungs drug penetration 
after inhalation with technetium-99mTc marked TOBI and pulmonary perfusion 
with albumin99mTc (phase I). Phase II: after physiotherapy with flutter, the same 
procedure was done one month later. The efficiency of marked TO131-99mTc 
was 87%. 
Results: 24 patients (12 males). Mean age (12.85 SD 6.64) ranged from 5 27 years. 
Delta F 508 homozygous: 7 patients, Delta F heterozygous: 13 patients, other 
mutations: 4 patients. TO13I pulmonary deposition was lower in all patients of 
phase II with more high significance in heterozygous. (Homozygous: p 0.310, 
heterozygous: p 0.043, others mutations:p 0.198). 
Conclusion: Physiotherapy with flutter and inhaled salbutamol, immediately before 
TO13I inhalation makes the TO13I pulmonary deposition less efficient in heterozy- 
gous CF patients when compared with CF homozygous and others mutation. 
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1~ Long-term administration of nebulised tobramycin in patients 
with Cystic Fibrosis 
A. Chuchalin 1 , K. Gyurkovics 2, H. Mazurek 3, G. Varoli 4, RA. Monici Preti 4. 
1Scientific Research Pulmonology Institute, Russian State Medical Universily, 
Moscow, Russia; 2pulmonology HosTital, Mosdds, Hungary; 3Bronchiology and 
Cystic Fibrosis', Department of National Research Institute for Tubercolosis and 
Lung Diseases', Rabka, Poland; 4Medical Department Chiesi Farmaceutici S.p.A., 
Parma, Italy 
Aims: A new highly concentrated aerosolised tobramycin (300mg/4ml) was as- 
sessed in a 24-week study period (4 on cycles plus 4 off cycles) in patients with 
cystic fibrosis and Pseudomonas aeruginosa (PA) infection. 
Methods: In a multicentre, double blind, placebo-controlled design study, 247 
patients were randomised to a b.i.d, treatment with tobramycin or placebo, in 
addition to other anti-pseudomonal therapies. Pulmonary function, PA susceptibility, 
hospitalisation, ototoxicity and nephrotoxicity were monitored. 
Results: In the tobramycin group, mean forced expiratory volume in one second 
%predicted normal increased from baseline of 11% at week 20, compared to 1% 
in the placebo group (p < 0.001 between groups), as well as forced vital capacity 
(p 0.022). Outcome of microbiology (PA eradication, persistence, superinfection) 
showed a statistically significant difference (p 0.024) in favour of the tobramycin 
group at week 20, with a lower patient hospitalization (p 0.002). No significant 
changes in serum creatinine and auditory function were detected. 
Conclusions: Long-term, intermittent administration f aerosolised tobramycin m- 
proved pulmonary function and microbiological outcome, decreased hospitalisation 
and was well tolerated. 
I •  Comparison of Pari kC-Star and -Plus nebulisers delivering 
2.5 mg recombinant human deoxyribonuclease (rhDNase) 
M.R. Elkins 1 , RT.R Bye 1,2. 1Department of ResTiratory Medicine, Royal Prince 
Aljbed Hospital, 2 Woolcock Institute of Medical Research, Sydney, Australia 
Aims; The Pari LC-Star nebuliser has a smaller particle size and a higher espirable 
fraction than the Pari LC-Plus nebuliser. Despite this, some CF centres recommend 
the LC-Plus for the delivery of rhDNase because of faster output than the LC- 
Star. However, this recommendation is based on an unpublished study in which the 
nebulisers were compared in the nebulisation of 8 mL of normal saline. Our aim 
was therefore to compare the output of the LC-Star and -Plus nebulisers delivering 
a dose of rhDNase. 
Methods; Part A: In a cross-over trial, ten patients with stable CF lung disease 
inhaled 2.5 nag of rhDNase via LC-Star and -Plus nebulisers, order randomised. 
Part B: Six LC-Star and six LC-Plus nebulisers were clamped upright on a benchtop 
and nebulised 2.5 nag of rhDNase running on medical air at 6 L/rain. For each part 
of the study, the nebulisers wet weighed before and after the rhDNase was loaded, 
and after each minute of the nebulisation period. Both nebulisers have a "dead 
volume", so the time taken to deliver 85% of the loaded dose (by weight) was 
calculated. 
Results; Part A: The mean (SD) time taken to deliver 85% of the loaded dose was 
10 (2) minutes for the LC-Star and 12 (3) miunutes for the LC-Plus, P 0.024. 
Part t3: The mean (SD) time taken to deliver 85% of the loaded dose was 8 (2) 
minutes for the LC-Star and 9 (2) minutes for the LC-Plus, P 0.89. 
Conclusions; In clinical use, the LC-Star delivers a single dose of rhDNase 
marginally more rapidly than the LC-Plus. In the benchtop setting, the nebulisers 
deliver a single dose of rhDNase at comparable rates. On the basis of output rates for 
rhDNase in this study, the LC-Plus should not be recommended oevr the LC-Star. 
1• Aerosolized tobramycin in the treatment of patients with 
Cystic Fibrosis and Pseudomonas aeruginosa infection 
G. Lenoir 1 , N. Aryayev 2, G. Varoli 3, R Monici Preti 3. 1M~decine Interne et 
Mucoviscidose, Service de Pddiatrie Gdndrale, H@ital Necke~ Paris', France; 
2Odessa Region Clinical ChildrenX' Hospital, Odessa, Ukraine; 3Medical 
Department, Chiesi Farmaceutici S.p.A., Parma, Italy 
Aims; To evaluate the safety and efficacy of a new highly concentrated aerosolised 
tobramycin (300rag in 4ml NaC1 solution 0.45%) in patients with cystic fibrosis 
and Pseudomonas aeruginosa (PA) infection. 
Methods: Fifty-nine patients were randomised in a multicentre, double blind, 
placebo-controlled design study to a b.i.d, treatment with tobramycin or placebo, 
over a 4-week period plus a 4-week run-out period without any treatment. Pul- 
monary function, PA susceptibility, ototoxicity and nephrotoxicity were monitored. 
Results: Tobramycin administration was associated with a marked increase of 
forced expiratory volume in one second % predicted normal from baseline after 
two (16.11%, 95% CI: 7.94 to 19.09; p 0.002 between groups) and four (13.52%, 
95% CI: 10.99 to 21.23; p 0.003 between groups) weeks of treatment, as well 
as forced vital capacity (FVC) (p 0.017 between groups at week 4) and forced 
expiratory flow at 25% and 75% FVC (p 0.004 between groups at week 4). These 
increases were not maintained at week 8. Outcome of microbiology (PA eradication, 
persistence, superinfection) showed a statistically significant difference (p 0.033) 
in favour of the tobramycin group at week 4, not maintained at week 8. Neither 
ototoxicity nor nephrotoxicity were detected. 
Conclusions: The 4-week treatment with highly concentrated aerosolised to- 
bramycin was well tolerated and effective in improving pulmonary function and 
microbiological outcome. 
